Program
cenegermin
Also written as “Cenegermin”, “cenegermin-bkbj” and “OXERVATE® 0.002%”.
Its studies are mostly in Dry Eye Syndromes · Optic Neuropathy, Ischemic · Conjunctivitis, Allergic · Corneal Diseases · Corneal Ulcer, led by Dompé Farmaceutici S.p.A.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dompé Farmaceutici S.p.A | 62 open or running | phase 4since Jul 21, 2020 | Jul 21, 2020 | Sep 2027phase 3 · NCT07453888 |
Also a collaborator on its studies: dompe-us-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 21, 2020First study: phase 4 study in Corneal DiseasesFirst studyNCT04485546 · 37 enrolled · United States
- Nov 15, 20212 phase 3 studies in Dry Eye SyndromesNCT05136170, NCT05133180
- May 8, 2024Phase 4 study in Corneal UlcerNCT06411145
- Mar 2, 20262 phase 3 studiesNCT07453888, NCT07519902
Ahead
- Sep 2027Primary completion: phase 3 study in Optic Neuropathy, IschemicNCT07453888
- Dec 2027Primary completion: phase 3 study in Conjunctivitis, AllergicNCT07519902
TargetBeta
“Neurotrophic tyrosine kinase receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| taletrectinibrule | Nuvation Bio | phase 3 | 11 |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07519902Conjunctivitis, Allergic · United States, Argentina, Czechia and more | 3 | Recruiting | Dec 2027 | 150 |
| NCT07453888Optic Neuropathy, Ischemic · United States, Australia, South Korea and more | 3 | Recruiting | Sep 2027 | 272 |
| NCT06411145Corneal Ulcer | 4 | Withdrawn | Nov 12, 2024 | 0 |
| NCT05136170Dry Eye Syndromes · United States, Italy | 3 | Completed | May 24, 2023 | 85 |
| NCT05133180Dry Eye Syndromes · United States, Italy | 3 | Completed | Sep 22, 2022 | 104 |
| NCT04485546Corneal Diseases · United States | 4 | Completed | Sep 30, 2021 | 37 |
How it is read
Names in the registry
- “Cenegermin”, 3 entries
- “cenegermin-bkbj”, 1 entry
- “OXERVATE® 0.002%”, 1 entry
- “Oxervate”, 1 entry
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 2 studies
- Optic Neuropathy, Ischemic, 1 study
- Conjunctivitis, Allergic, 1 study
- Corneal Diseases, 1 study
- Corneal Ulcer, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.